CTLA4 and central nervous system cancer: Combination immunotherapies have also been tested as a treatment in murine models of glioma: the combination of GVAX followed by CTLA-4 blockade resulted in 50% long-term survival in a murine model of intracranial glioma, whereas CTLA-4 blockade alone did not improve survival in established tumors [26].